<ul>
<li>你需要了解的突破性动量股票</li>
</ul>
<p>uniQure N.V.（纳斯达克：QURE - 免费报告）- HC Wainwright 的股票分析师在 5 月 6 日星期三发布的报告中发布了对 uniQure 2027 年第一季度收益的预测。HC Wainwright 分析师 P. Trucchio 预测该生物技术公司本季度每股收益为（$0.95）。HC Wainwright 目前对该股票的评级为 “买入”，目标价格为 $50.00。对 uniQure 当前全年的收益共识估计为每股（$3.60）。HC Wainwright 还对 uniQure 2027 年第二季度的收益进行了预测，预计每股收益为（$0.96），2027 年第三季度的收益为（$0.93），2027 年第四季度的收益为（$0.90）。</p>
<p>uniQure（纳斯达克：QURE - 获取免费报告）最近在 5 月 5 日星期二宣布了其季度收益结果。该生物技术公司报告本季度每股收益为（$0.85），超出分析师共识估计的（$0.88）$0.03。uniQure 的净利润率为负 1,154.42%，股本回报率为负 145.81%。该公司本季度的收入为 356 万美元，而分析师的预期为 521 万美元。</p>
<ul>
<li>QURE：分析师为何认为在单日上涨 250% 后有高达 63% 的上涨空间</li>
</ul>
<p>QURE 一直是其他一些研究报告的主题。TD Cowen 在 3 月 3 日星期二的研究报告中重申了对 uniQure 股票的 “买入” 评级。Wolfe Research 在 2 月 23 日星期一的研究报告中开始覆盖 uniQure 股票。他们对该股票给予了 “同行表现” 评级。华尔街 Zen 在 3 月 28 日星期六的报告中将 uniQure 的评级从 “卖出” 上调至 “持有”。加拿大皇家银行在 3 月 9 日星期一的报告中将 uniQure 的评级从 “行业表现” 上调至 “跑赢大盘”，并将其目标价格从 $11.00 提高至 $35.00。最后，Leerink Partners 在 3 月 2 日星期一的报告中重新发布了 “跑赢大盘” 评级，并对 uniQure 股票设定了 $35.00 的目标价格。十位投资分析师对该股票给予了买入评级，六位给予了持有评级，一位给予了卖出评级。根据 MarketBeat.com 的数据，该股票的共识评级为 “适度买入”，共识目标价格为 $42.83。</p>
<p><strong>查看我们关于 uniQure 的最新报告</strong></p>
<h2>uniQure 股票上涨 7.8%</h2>
<p>QURE 的股票在星期四以 $22.82 开盘。uniQure 的 52 周低点为 $8.73，52 周高点为 $71.50。该公司的市值为 14.4 亿美元，市盈率为 -6.56，贝塔值为 0.87。该公司的 50 天简单移动平均线为 $16.67，200 天简单移动平均线为 $24.97。该公司的债务与股本比率为 0.33，速动比率为 10.43，流动比率为 10.40。</p>
<h2>机构投资者对 uniQure 的看法</h2>
<p>几家大型投资者最近调整了对 QURE 的持股。先锋集团（Vanguard Group Inc.）在第三季度将其在 uniQure 股票中的持股增加了 15.7%。先锋集团目前拥有 1,125,108 股该生物技术公司的股票，价值 65,673,000 美元，此前在上个季度又购买了 152,417 股。阿伯丁集团（Aberdeen Group plc）在第四季度将其在 uniQure 股票中的持股增加了 25.1%。阿伯丁集团目前拥有 3,678,640 股该生物技术公司的股票，价值 88,030,000 美元，此前在上个季度又购买了 738,897 股。奎因机会合伙公司（Quinn Opportunity Partners LLC）在第三季度购买了 uniQure 的新头寸，价值 6,281,000 美元。法拉隆资本管理公司（Farallon Capital Management LLC）在第三季度将其在 uniQure 股票中的持股增加了 3,935.7%。法拉隆资本管理公司目前拥有 565,000 股该生物技术公司的股票，价值 32,979,000 美元，此前在上个季度又购买了 551,000 股。最后，达尔文全球管理有限公司（Darwin Global Management Ltd.）在第三季度购买了 uniQure 的新头寸，价值 23,760,000 美元。目前 78.83% 的股票由机构投资者和对冲基金持有。</p>
<h2>uniQure 的内部买卖情况</h2>
<p>在其他 uniQure 的新闻中，首席财务官 Christian Klemt 在 3 月 4 日星期三进行了一笔交易，出售了 12,000 股公司的股票。这些股票以平均价格 $9.06 出售，总价值为 $108,720.00。交易完成后，首席财务官直接持有该公司 226,581 股股票，价值约为 $2,052,823.86。这代表其持股减少了 5.03%。该出售在与 SEC 的法律文件中披露，可以通过此链接访问。此外，首席执行官 Matthew C. Kapusta 在 3 月 4 日星期三进行了一笔交易，出售了 14,581 股公司的股票。这些股票以平均价格 $9.06 出售，总交易额为 $132,103.86。交易完成后，首席执行官持有该公司 660,658 股股票，价值约为 $5,985,561.48。这笔交易代表其持股减少了 2.16%。该出售的 SEC 文件提供了更多信息。在过去的九十天里，内部人士出售了价值 $722,734 的 49,396 股公司股票。目前 4.79% 的股票由公司内部人士持有。</p>
<h2>uniQure 公司简介</h2>
<p>（获取免费报告）</p>
<p>uniQure N.V. 是一家生物技术公司，专注于为有严重医疗需求的患者开发和商业化基因疗法。该公司利用其专有的腺病毒相关病毒（AAV）载体平台，设计单剂量治疗，旨在解决疾病的根本遗传原因，而不仅仅是管理症状。其最先进的项目 Hemgenix®（etranacogene dezaparvovec）已获得美国和欧洲的监管批准，适用于患有 B 型血友病的成人患者，标志着首个针对出血疾病的基因疗法之一进入市场。</p>
<p>除了血友病 B，uniQure 的产品线还包括针对稀有且严重疾病的临床前和临床阶段候选药物，如芳香族 L-氨基酸脱羧酶 (AADC) 缺乏症、亨廷顿舞蹈症和帕金森病。</p>
<h2>另见</h2>
<ul>
<li>五只我们认为比 uniQure 更好的股票</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UVVSRQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UVVSRQ"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 uniQure 吗？</h2>
<p>在考虑 uniQure 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 uniQure 并不在名单上。</p>
<p>虽然 uniQure 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

QURE

标普生物技术 ETF - SPDR

2 倍做多纳斯达克生物技术 ETF - ProShares

动态生物技术与基因组 ETF - Invesco

生物科技 ETF - VanEck Vectors

医药突破 ETF - ALPS

纽交所高增长板生物技术指数 ETF - First Trust

纳斯达克生物科技指数 ETF - iShares Nasdaq

IBBQ

标普生物技术 3 倍做多 - Direxion

<p>HC Wainwright 预测 uniQure N.V.（NASDAQ:QURE）将在 2027 年第一季度报告每股收益为（$0.95），维持 “买入” 评级，目标价格为 $50.00。全年共识预期为每股（$3.60）。该公司最近报告的第一季度每股收益为（$0.85），超出预期。分析师的评级各不相同，普遍共识为 “适度买入”，目标价格为 $42.83。机构投资者持有该股票的 78.83%，最近 CFO Christian Klemt 报告了内部人士的卖出情况</p>

<ul>
<li>Breakout Momentum Plays You Need to Know About</li>
</ul>
<div class="lb-trans"><ul>
<li>你需要了解的突破性动量股票</li>
</ul>
</div><p>uniQure N.V. (NASDAQ:QURE - Free Report) - Stock analysts at HC Wainwright issued their Q1 2027 earnings estimates for shares of uniQure in a report released on Wednesday, May 6th. HC Wainwright analyst P. Trucchio forecasts that the biotechnology company will post earnings of ($0.95) per share for the quarter. HC Wainwright currently has a &#34;Buy&#34; rating and a $50.00 target price on the stock. The consensus estimate for uniQure's current full-year earnings is ($3.60) per share. HC Wainwright also issued estimates for uniQure's Q2 2027 earnings at ($0.96) EPS, Q3 2027 earnings at ($0.93) EPS and Q4 2027 earnings at ($0.90) EPS.</p>
<div class="lb-trans"><p>uniQure N.V.（纳斯达克：QURE - 免费报告）- HC Wainwright 的股票分析师在 5 月 6 日星期三发布的报告中发布了对 uniQure 2027 年第一季度收益的预测。HC Wainwright 分析师 P. Trucchio 预测该生物技术公司本季度每股收益为（$0.95）。HC Wainwright 目前对该股票的评级为 “买入”，目标价格为 $50.00。对 uniQure 当前全年的收益共识估计为每股（$3.60）。HC Wainwright 还对 uniQure 2027 年第二季度的收益进行了预测，预计每股收益为（$0.96），2027 年第三季度的收益为（$0.93），2027 年第四季度的收益为（$0.90）。</p>
</div><p>uniQure (NASDAQ:QURE - Get Free Report) last announced its quarterly earnings results on Tuesday, May 5th. The biotechnology company reported ($0.85) EPS for the quarter, beating analysts' consensus estimates of ($0.88) by $0.03. uniQure had a negative net margin of 1,154.42% and a negative return on equity of 145.81%. The business had revenue of $3.56 million for the quarter, compared to analyst estimates of $5.21 million.</p>
<div class="lb-trans"><p>uniQure（纳斯达克：QURE - 获取免费报告）最近在 5 月 5 日星期二宣布了其季度收益结果。该生物技术公司报告本季度每股收益为（$0.85），超出分析师共识估计的（$0.88）$0.03。uniQure 的净利润率为负 1,154.42%，股本回报率为负 145.81%。该公司本季度的收入为 356 万美元，而分析师的预期为 521 万美元。</p>
</div><ul>
<li>QURE: Why Analysts See Up to 63% Upside After 250% Single-Day Pop</li>
</ul>
<div class="lb-trans"><ul>
<li>QURE：分析师为何认为在单日上涨 250% 后有高达 63% 的上涨空间</li>
</ul>
</div><p>QURE has been the topic of a number of other research reports. TD Cowen reiterated a &#34;buy&#34; rating on shares of uniQure in a research note on Tuesday, March 3rd. Wolfe Research started coverage on shares of uniQure in a research note on Monday, February 23rd. They issued a &#34;peer perform&#34; rating on the stock. Wall Street Zen raised shares of uniQure from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a report on Saturday, March 28th. Royal Bank Of Canada raised shares of uniQure from a &#34;sector perform&#34; rating to an &#34;outperform&#34; rating and boosted their price objective for the company from $11.00 to $35.00 in a report on Monday, March 9th. Finally, Leerink Partners reissued an &#34;outperform&#34; rating and issued a $35.00 price objective on shares of uniQure in a report on Monday, March 2nd. Ten investment analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $42.83.</p>
<div class="lb-trans"><p>QURE 一直是其他一些研究报告的主题。TD Cowen 在 3 月 3 日星期二的研究报告中重申了对 uniQure 股票的 “买入” 评级。Wolfe Research 在 2 月 23 日星期一的研究报告中开始覆盖 uniQure 股票。他们对该股票给予了 “同行表现” 评级。华尔街 Zen 在 3 月 28 日星期六的报告中将 uniQure 的评级从 “卖出” 上调至 “持有”。加拿大皇家银行在 3 月 9 日星期一的报告中将 uniQure 的评级从 “行业表现” 上调至 “跑赢大盘”，并将其目标价格从 $11.00 提高至 $35.00。最后，Leerink Partners 在 3 月 2 日星期一的报告中重新发布了 “跑赢大盘” 评级，并对 uniQure 股票设定了 $35.00 的目标价格。十位投资分析师对该股票给予了买入评级，六位给予了持有评级，一位给予了卖出评级。根据 MarketBeat.com 的数据，该股票的共识评级为 “适度买入”，共识目标价格为 $42.83。</p>
</div><p><strong>Check Out Our Latest Report on uniQure</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 uniQure 的最新报告</strong></p>
</div><h2>uniQure Stock Up 7.8%</h2>
<div class="lb-trans"><h2>uniQure 股票上涨 7.8%</h2>
</div><p>Shares of QURE opened at $22.82 on Thursday. uniQure has a 52 week low of $8.73 and a 52 week high of $71.50. The firm has a market cap of $1.44 billion, a P/E ratio of -6.56 and a beta of 0.87. The firm's 50-day simple moving average is $16.67 and its 200 day simple moving average is $24.97. The company has a debt-to-equity ratio of 0.33, a quick ratio of 10.43 and a current ratio of 10.40.</p>
<div class="lb-trans"><p>QURE 的股票在星期四以 $22.82 开盘。uniQure 的 52 周低点为 $8.73，52 周高点为 $71.50。该公司的市值为 14.4 亿美元，市盈率为 -6.56，贝塔值为 0.87。该公司的 50 天简单移动平均线为 $16.67，200 天简单移动平均线为 $24.97。该公司的债务与股本比率为 0.33，速动比率为 10.43，流动比率为 10.40。</p>
</div><h2>Institutional Investors Weigh In On uniQure</h2>
<div class="lb-trans"><h2>机构投资者对 uniQure 的看法</h2>
</div><p>Several large investors have recently modified their holdings of QURE. Vanguard Group Inc. lifted its stake in shares of uniQure by 15.7% in the third quarter. Vanguard Group Inc. now owns 1,125,108 shares of the biotechnology company's stock valued at $65,673,000 after buying an additional 152,417 shares in the last quarter. Aberdeen Group plc lifted its stake in shares of uniQure by 25.1% in the fourth quarter. Aberdeen Group plc now owns 3,678,640 shares of the biotechnology company's stock valued at $88,030,000 after buying an additional 738,897 shares in the last quarter. Quinn Opportunity Partners LLC bought a new position in shares of uniQure in the third quarter valued at $6,281,000. Farallon Capital Management LLC lifted its stake in shares of uniQure by 3,935.7% in the third quarter. Farallon Capital Management LLC now owns 565,000 shares of the biotechnology company's stock valued at $32,979,000 after buying an additional 551,000 shares in the last quarter. Finally, Darwin Global Management Ltd. bought a new position in shares of uniQure in the third quarter valued at $23,760,000. 78.83% of the stock is currently owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>几家大型投资者最近调整了对 QURE 的持股。先锋集团（Vanguard Group Inc.）在第三季度将其在 uniQure 股票中的持股增加了 15.7%。先锋集团目前拥有 1,125,108 股该生物技术公司的股票，价值 65,673,000 美元，此前在上个季度又购买了 152,417 股。阿伯丁集团（Aberdeen Group plc）在第四季度将其在 uniQure 股票中的持股增加了 25.1%。阿伯丁集团目前拥有 3,678,640 股该生物技术公司的股票，价值 88,030,000 美元，此前在上个季度又购买了 738,897 股。奎因机会合伙公司（Quinn Opportunity Partners LLC）在第三季度购买了 uniQure 的新头寸，价值 6,281,000 美元。法拉隆资本管理公司（Farallon Capital Management LLC）在第三季度将其在 uniQure 股票中的持股增加了 3,935.7%。法拉隆资本管理公司目前拥有 565,000 股该生物技术公司的股票，价值 32,979,000 美元，此前在上个季度又购买了 551,000 股。最后，达尔文全球管理有限公司（Darwin Global Management Ltd.）在第三季度购买了 uniQure 的新头寸，价值 23,760,000 美元。目前 78.83% 的股票由机构投资者和对冲基金持有。</p>
</div><h2>Insider Buying and Selling at uniQure</h2>
<div class="lb-trans"><h2>uniQure 的内部买卖情况</h2>
</div><p>In other uniQure news, CFO Christian Klemt sold 12,000 shares of the company's stock in a transaction that occurred on Wednesday, March 4th. The shares were sold at an average price of $9.06, for a total value of $108,720.00. Following the completion of the transaction, the chief financial officer directly owned 226,581 shares in the company, valued at approximately $2,052,823.86. This represents a 5.03% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Matthew C. Kapusta sold 14,581 shares of the company's stock in a transaction that occurred on Wednesday, March 4th. The shares were sold at an average price of $9.06, for a total transaction of $132,103.86. Following the completion of the transaction, the chief executive officer owned 660,658 shares of the company's stock, valued at approximately $5,985,561.48. This trade represents a 2.16% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 49,396 shares of company stock worth $722,734. 4.79% of the stock is currently owned by company insiders.</p>
<div class="lb-trans"><p>在其他 uniQure 的新闻中，首席财务官 Christian Klemt 在 3 月 4 日星期三进行了一笔交易，出售了 12,000 股公司的股票。这些股票以平均价格 $9.06 出售，总价值为 $108,720.00。交易完成后，首席财务官直接持有该公司 226,581 股股票，价值约为 $2,052,823.86。这代表其持股减少了 5.03%。该出售在与 SEC 的法律文件中披露，可以通过此链接访问。此外，首席执行官 Matthew C. Kapusta 在 3 月 4 日星期三进行了一笔交易，出售了 14,581 股公司的股票。这些股票以平均价格 $9.06 出售，总交易额为 $132,103.86。交易完成后，首席执行官持有该公司 660,658 股股票，价值约为 $5,985,561.48。这笔交易代表其持股减少了 2.16%。该出售的 SEC 文件提供了更多信息。在过去的九十天里，内部人士出售了价值 $722,734 的 49,396 股公司股票。目前 4.79% 的股票由公司内部人士持有。</p>
</div><h2>uniQure Company Profile</h2>
<div class="lb-trans"><h2>uniQure 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.</p>
<div class="lb-trans"><p>uniQure N.V. 是一家生物技术公司，专注于为有严重医疗需求的患者开发和商业化基因疗法。该公司利用其专有的腺病毒相关病毒（AAV）载体平台，设计单剂量治疗，旨在解决疾病的根本遗传原因，而不仅仅是管理症状。其最先进的项目 Hemgenix®（etranacogene dezaparvovec）已获得美国和欧洲的监管批准，适用于患有 B 型血友病的成人患者，标志着首个针对出血疾病的基因疗法之一进入市场。</p>
</div><p>Beyond hemophilia B, uniQure's pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington's disease, and Parkinson's disease.</p>
<div class="lb-trans"><p>除了血友病 B，uniQure 的产品线还包括针对稀有且严重疾病的临床前和临床阶段候选药物，如芳香族 L-氨基酸脱羧酶 (AADC) 缺乏症、亨廷顿舞蹈症和帕金森病。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另见</h2>
</div><ul>
<li>Five stocks we like better than uniQure</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们认为比 uniQure 更好的股票</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UVVSRQ" alt="" original-src="https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx?Prefix=NASDAQ&amp;Symbol=QURE"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in uniQure Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 uniQure 吗？</h2>
</div><p>Before you consider uniQure, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 uniQure 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and uniQure wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 uniQure 并不在名单上。</p>
</div><p>While uniQure currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 uniQure 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

HC Wainwright 对 Uniqure 第一季度收益的预测是什么？